Takeda Pharmaceutical Co Ltd
TSE:4502
Takeda Pharmaceutical Co Ltd
Income from Continuing Operations
Takeda Pharmaceutical Co Ltd
Income from Continuing Operations Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Income from Continuing Operations | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Takeda Pharmaceutical Co Ltd
TSE:4502
|
Income from Continuing Operations
¥208.2B
|
CAGR 3-Years
-22%
|
CAGR 5-Years
73%
|
CAGR 10-Years
14%
|
|
|
Daiichi Sankyo Co Ltd
TSE:4568
|
Income from Continuing Operations
¥245.5B
|
CAGR 3-Years
37%
|
CAGR 5-Years
11%
|
CAGR 10-Years
14%
|
|
|
Otsuka Holdings Co Ltd
TSE:4578
|
Income from Continuing Operations
¥347.3B
|
CAGR 3-Years
39%
|
CAGR 5-Years
21%
|
CAGR 10-Years
9%
|
|
|
S
|
Shionogi & Co Ltd
TSE:4507
|
Income from Continuing Operations
¥167.5B
|
CAGR 3-Years
20%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
18%
|
|
|
Chugai Pharmaceutical Co Ltd
TSE:4519
|
Income from Continuing Operations
¥387.3B
|
CAGR 3-Years
9%
|
CAGR 5-Years
20%
|
CAGR 10-Years
22%
|
|
|
Astellas Pharma Inc
TSE:4503
|
Income from Continuing Operations
-¥57.4B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Takeda Pharmaceutical Co Ltd
Glance View
In the ever-evolving landscape of global pharmaceuticals, Takeda Pharmaceutical Co Ltd. stands as a robust and adaptive entity, blending a rich heritage with bold innovation. Originating from Japan, Takeda's journey began over two centuries ago, carving its niche by focusing on value-driven and research-led approaches in the pharmaceutical industry. With its headquarters in Tokyo, the company has fortified its position as one of the global leaders, largely due to its emphasis on research and development that spans across cutting-edge areas such as oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies. This innovation-centric strategy is not just a nod to the future, but a crucial component that allows Takeda to address pressing health challenges worldwide, continually expanding its pipeline with transformative therapies. Takeda's commercial model revolves around its diverse therapeutic portfolio and strategic collaborations, which are instrumental in capturing growth across various markets. By leveraging its scientific expertise and expanding technological capabilities, the company advances its core business segments while integrating augmented biotechnology solutions through strategic acquisitions and partnerships. The absorption of Shire, a prominent biotechnology firm, stands as a hallmark of Takeda's commitment to enhancing its presence in rare diseases and plasma-derived therapies, thereby widening its global footprint. This focus not only fuels revenue generation from innovative products but also ensures a multidimensional approach to market entry across pivotal regions. Through balancing its inventive drive with operational efficiency, Takeda efficiently monetizes its products, securing its status as a formidable player in the pharmaceutical domain.
See Also
What is Takeda Pharmaceutical Co Ltd's Income from Continuing Operations?
Income from Continuing Operations
208.2B
JPY
Based on the financial report for Dec 31, 2024, Takeda Pharmaceutical Co Ltd's Income from Continuing Operations amounts to 208.2B JPY.
What is Takeda Pharmaceutical Co Ltd's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 10Y
14%
Over the last year, the Income from Continuing Operations growth was 17%. The average annual Income from Continuing Operations growth rates for Takeda Pharmaceutical Co Ltd have been -22% over the past three years , 73% over the past five years , and 14% over the past ten years .
You don't have any saved screeners yet